INVESTOR FAQs
Can SCLERA technology provide intraocular sustained release of retinal biopharmaceuticals?
The SCLERA implant in the rabbit vitreous induces experimental retinal neovascularization (above photo). Delivering intraocular retinal biopharmaceuticals for an extended period of time is what SCLERA hopes to accomplish. Investment in the development of SCLERA intraocular implant technology for extended release of retinal therapeutics will help patients see longer as they age.
Can retinal biopharmaceuticals be released slowly for ameliorating neovascular AMD?
The SCLERA intraocular implant, which slowly releases selective human growth factors, is placed subchoroidally in the NHP eye (above photo). Further development of the SCLERA implant technology for extended long-term release of intraocular biopharmaceuticals will allow people to see their doctors less frequently.
Can retinal biopharmaceuticals be released slowly for ameliorating diabetic retinopathy?
Diabetic retinopathy is the most common cause of blindness in working adults. The SCLERA implant with its slow-releasing human growth factors in the mid-vitreous of the rabbit eye provides a valuable disease model in testing for drugs against proliferative diabetic retinopathy (above photo).
.